Comparative Pharmacology
Head-to-head clinical analysis: GLUCOTROL versus MICRONASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCOTROL versus MICRONASE.
GLUCOTROL vs MICRONASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptor 1 (SUR1) on ATP-sensitive potassium channels, causing depolarization and calcium influx. Also may increase peripheral insulin sensitivity.
Stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels, leading to membrane depolarization, calcium influx, and exocytosis of insulin.
Initial dose 5 mg orally once daily, increased by 2.5-5 mg increments weekly based on glycemic response; maximum 20 mg daily as single or divided doses (for doses >15 mg, administer in divided doses).
Initial dose: 2.5-5 mg orally once daily with breakfast. Maintenance: 1.25-20 mg daily in single or divided doses. Maximum: 20 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (mean 3.4 hours) in normal subjects; extended up to 8-12 hours in elderly or hepatic impairment due to reduced clearance.
Terminal elimination half-life: 10 hours (range 7-20); clinical context: duration of action may be prolonged in renal impairment.
Primarily renal: ~80% as metabolites (mainly 4-trans-hydroxyglipizide and 3-cis-hydroxyglipizide) and ~10% unchanged; fecal: ~10%.
Renal: approximately 50% as metabolites and unchanged drug; biliary/fecal: approximately 50% as metabolites.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic